Review Article
Role of MicroRNAs in Cardiac Disease with Stroke in Pregnancy

Umme Salma,1, Ahmed Baker A. Alshaikh,1 Muhammad Faleh Alanazi,2 Basil Mohammed Alomair,3 Mubarak Alruwaili,3 and Raed Alruwaili3

1Department of Obstetrics & Gynecology, College of Medicine, Jouf University, Sakaka, Saudi Arabia
2Department of Internal Medicine, Division of Radiology, College of Medicine, Jouf University, Sakaka, Saudi Arabia
3Department of Internal Medicine, College of Medicine, Jouf University, Sakaka, Saudi Arabia

Correspondence should be addressed to Umme Salma; drsalma10@yahoo.com

Received 12 July 2022; Accepted 30 August 2022; Published 12 September 2022

Academic Editor: Zhong-Bao Yang

Copyright © 2022 Umme Salma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pregnancy-related cardiovascular disease with stroke remains a considerable source of higher maternal morbidity and mortality occurs in periods of pregnancy, delivery, and postpartum. It is essential to counsel the mother before pregnancy by an expert cardiologist and obstetric team to discuss any event related to preexistent cardiac or past preeclampsia for estimation of maternal and fetal risks. In pregnancy, the cardiac state includes hypertensive disorders, ischemic heart disease, valvular disease, and postpartum stroke. The incidence of stroke is increasing in pregnancy, particularly in postpartum, and its strong relationship with hypertensive disorders of pregnancy (preeclampsia). The combined cardiologist and obstetric team requires during pregnancy mainly due to the approach to the management of a cardiac disease that subsequently prevents stroke postpartum. Therefore, a general perception of cardiac disease during pregnancy, delivery, and postpartum should be a core knowledge extent for all cardiovascular and clinicians. Many studies provided linked that deregulation of microRNAs (miRNAs) in maternal circulation and placenta tissue may development of pregnancy complications including preeclampsia considered a diagnostic marker. The desire of this review provides a detailed outline of current knowledge and dealing in this field with strength on the physiological changes during pregnancy.

1. Introduction

Directly or indirectly pregnancy-related cardiovascular disease (CVD) is considered a leading cause of maternal death in both developed and developing countries [1, 2]. In the last few decades, a greater number of postpartum hospitalization and maternal death notified considering cardiovascular disease. Globally, around 1%-4% of cardiovascular diseases may complicate pregnancy [3]. It has been evidenced that nearly 0.2–0.4% of CVD is affected among all pregnant women [4]. Several studies accounted that progressively growing pregnancy with CVD, because of the increased number of women with congenital heart disease, a certain combination in their reproductive age, and advancing maternal age which includes risk factors as multifetal pregnancies, hypertension, hypertensive disorders of pregnancy (HDP; gestational hypertension and preeclampsia), and diabetes mellitus [5, 6]. Besides, ischemic heart disease (IHD), among acute myocardial infarction (AMI), is an indirect cause of maternal death associated with CVD in western countries [7]. In developed countries, the data suggested that the type of CVD in pregnancy is commonly related to valvular heart disease, in both congenital and acquired [8]. Conversely, it has been demonstrated that hypertensive disorders of pregnancy (HDP) women have a greater risk of stroke long-term, and approximately 50% of pregnancy strokes are associated with preeclampsia or eclampsia [9–11]. Pregnancy stroke is considered a dangerous period because prolonged disability following pregnancy around 7.7% results in maternal death [10]. Preeclampsia women have notified the chance of risk
increased 2-fold development of stroke in their later life [11]. In 2011, a combination of the American Heart Association (AHA) and American Stroke Association reported that hypertensive disorder during pregnancy is considered a key risk factor for developing of cardiovascular diseases and advised to clinicians for routinely screen women who have a past of these complications [6]. It has been demonstrated that the expression of circulating miRNA altered during pregnancy is exaggerated by cardiac complications. In the past few years, the circulating miRNA become grown as a biomarker of diagnostic and prognosis value of cardiac failure [12], while a large number of studies published relations of miRNA with cardiac disease including preeclampsia, gestational hypertension, and postpartum cardiomyopathy. However, the present study reviews the miRNA and pregnancy-associated heart disease and stroke.

2. Cardiovascular Adaptations to Normal Pregnancy

Pregnancy altered the physiological function of the cardiovascular system by raising the metabolic demand and assurance uteroplacental adequate circulation for proper growth and development of the fetus. The preliminary physiologic change has seen lower systemic and pulmonary vascular resistance that subsequently lowers mean arterial blood pressure [13]. Therefore, a 30%-50% increase in the circulating plasma volume at 12 gestational weeks is a peak at the time of the third trimester. Meanwhile, heart rate increased by around 10 beats per minute [14]. Consequently, these changes may responsible for raising cardiac output which is shown in Figure 1, although the peak level of cardiac output detected in the third trimester of pregnancy was nearly above 50% at prepregnancy levels and a 25% consistent increase in stroke volume [15]. Additionally, a further 80% of cardiac output increased during delivery due to rapid and significant hemodynamic changes in the mother. However, with either vaginal or cesarean delivery, the hemodynamics returns to baseline approximately 2-4 weeks later.

3. Pregnancy in Advanced Maternal Age Impact on Cardiovascular Disease

In the aging state, the biological function diminishes which subsequently affects the function of the endothelium and increases the activities of the sympathetic nervous system, subsequently leading to arterial stiffness and hypertension [16–18]. Hence, the advanced maternal aged cardiovascular system decreases the adaptation capacity to the vascular system during a physiological alteration in pregnancy. Unfortunately, there is insufficient data available in the research field about the relationship between advanced maternal age and the function of the vascular system in pregnancy. Meanwhile, some studies’ evidence of the perception of vascular adaptation may be exaggerated by maternal age [19]. Data from survey analysis on 884 healthy pregnant women the ages ranging from 15 to 45 years detected a significant association between mean uterine artery resistance (as measured with pulsatility index (PI)) and maternal age, who is over the age of 35 years [19]; therefore, it is proposed that uterine artery resistances over advanced maternal age may have potential adverse effect on outcomes of pregnancy. On the other hand, the placenta is important for fetal growth and development; inadequate placental function may oppose effects on pregnancy outcomes including preeclampsia and stillbirth. Therefore, it is suggested that pregnancy at maternal age may be responsible for cardiac complications during pregnancy and also postpartum which is shown in Figure 2.

4. Cardiac Events and Stroke in Pregnancy

Details are represented in a flowchart in Figure 3.

4.1. Hypertensive Disorders in Pregnancy. The delivery is approximately 912 per 10000 with hypertensive pregnant mothers estimated as a common disorder according to hospital data in the United States. According to the American College of Obstetricians and Gynecologists (ACOG), HDP is divided into four categories such as chronic hypertension, gestational hypertension, preeclampsia/ecclampsia, and hypertension with superimposed preeclampsia [20]. However, preeclampsia/ecclampsia significantly raises mortality in both mother and fetal. Preeclampsia is expressed when raising systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg after 20 weeks of pregnancy with no previous history of hypertension. These circumstances usually affect approximately 2% to 8% of all pregnancies [21]. It has been reported that preeclampsia is subsequently 71%, 2.5-fold, and 4-fold risk for death of cardiovascular disease, coronary artery disease, and heart failure, respectively. Several studies evidence that regular exercise, diet, modified lifestyle, and cessation of smoking may reduce the risk of CVD and also prevent preeclampsia which was also suggested by both ACOG and AHA [20], although many studies recommended a low dose of aspirin in case of preterm birth at <34 weeks, late first trimester, chronic hypertension, and diabetes mellitus, which subsequently diminishes the danger of maternal myocardial ischemia, heart failure, and stroke. Conversely, selected drugs depend on the severity of hypertension including nifedipine, methyldopa, and labetalol that are essential for less-severe hypertension as considered first-line antihypertensive drugs, while labetalol and hydralazine are intravenously recommended for severe hypertension. Moreover, it is demanding antihypertensive therapy for pregnant mothers with HDP and continues postpartum for around 1-2 weeks.

4.2. Ischemic Heart Disease in Pregnancy (IHD). Pregnancy with IHD is unlikely to develop but potentially dangerous state. Acute myocardial infarction has a 3- to 4-fold risk during pregnancy, while some studies evidence that per 100000 deliveries with IHD, about 2.8 to 8.1% may lead to an increase in the death rate by approximately 4.5% to 7.3% [22]. Several studies reported that acute myocardial infarction in pregnancy most probably causes myocardial infarction along nonobstructive coronary and spontaneous dissection of a coronary artery during pregnancy that is mostly occurring in the third trimester and postpartum.
The treatment of IHD depends on patients’ clinical presentation which is organized by the multidisciplinary team. According to a survey in 2016 in the United Kingdom, maternal mortality is the highest cause of ischemic heart disease (IHD) among one-fifth of heart disease with pregnancy being higher related to older age around 40 years or over. It is demonstrated during pregnancy, acute myocardial infarction is a risk that was compared with nonpregnant in the same age group [14]. In the United Kingdom, the obstetrics survey on one hundred fifty pregnant women identified ST-segment elevation MI (STEMI) as most commonly found compared to non-ST-segment elevation MI (NSTEMI) around the third trimester or postpartum showing approximately one-fifth of heart disease around the country. Most of the studies reviewed IHD in pregnancy in developed countries and identified the women with AMI due to one of the risk factors responsible for 40% older than 35 years, and parous women in developing countries showed smoking and reproductive age being common in nearly 15% [24]. A similar report was found in a study on 100 pregnant women with MI and 45% due to smoking causes. The principal management is the same for both pregnant and nonpregnant period [23].

Figure 1: Physiological change in pregnancy.

Figure 2: Advance maternal age has an impact on cardiac adaptation in pregnancy considered to have cardiac complications.
conditions which are represented in diagram 1. Besides, many studies recommended combination teams including obstetricians, cardiologists, obstetric anesthetists, and neonatal specializing in management from early to end of delivery. Low doses of aspirin below 150 mg/day are safe during pregnancy, while there was no extensive report about clopidogrel in pregnancy but few report evidence of no fetal toxicity produced after using clopidogrel during pregnancy. Additionally, primary percutaneous coronary intervention was done with stent implantation treatment for STEMI, although some researchers suggested using lead shielding to decrease the exposure to radiation when performing coronary angiography on the fetus. Conversely, several medications are considered safe during pregnancy and lactation, which also prevent further secondary cardiovascular disease (Table 1).

4.3. Valvular Heart Disease in Pregnancy. In the developing country, 80% development of valvular heart disease and 50% causes of maternal death during pregnancy, rheumatic fever is the main cause of these that are seen the first time during pregnancy [7]. Generally, in normal cardiac function, the regurgitant lesions are well tolerated during pregnancy, and the stenotic lesion is considered at higher risk of decompen- sation during pregnancy due to limited increase of cardiac output leading to increase gradients of transvalvular and upstream lesions pressure that subsequently decreases the tolerated in pregnancy [25]. However, rheumatic mitral stenosis is poorly tolerated in the pregnancy state which is the main fact for higher maternal mortality of cardiac causes in developing countries. The symptoms of mitral stenosis (MS) in the pregnant state present exertional dyspnoea and as well postural symptoms such as paroxysmal nocturnal dyspnoea and orthopnea. In the case of pulmonary edema, the middiastolic rumbling murmur is difficult to recognize at the level of apex, while left atrium enlargement and bifi- d P wave are essential to be detected by radiology and ECG investigations, respectively. Conversely, pulmonary edema is a risk during pregnancy because vascular resistance increases in the last trimester leading to a high filling pressure on the left side. Additionally, this risk further occurs during labor and postpartum immediately due to hyperdynamic circulation and blood volume increase at the third stage of labor. The principal management depends on the severity of MS; if moderate stenosis (valve area 1.0–1.5 cm²) was detected, then either regular close monitoring or intervention is required. In the case of asymptomatic and severe mitral stenosis (valve area < 1.0 cm²), the best method is elective percutaneous balloon valvuloplasty performed during the midtrimester or 20 weeks earlier of gestation [26]. However, open-heart surgery is ready for maternal life-threatening conditions. In pregnancy state, aortic stenosis (AS) is very rare, and asymptomatic AS during pregnancy is well tolerated though it is a severe condition. It is suggested that pregnancy may continue in the asymptomatic state when left ventricular size, function, and exercise test results are normal. Besides, the management of persistent symptoms of AS during pregnancy is percutaneous valvuloplasty. However, the treatment protocol for life-threatening conditions is the replacement of a valve followed by an early cesarean section. Also, for severe symptomatic AS, the delivery should be performed by cesarean section. Furthermore, aortic regurgitation (AR) mainly due to congenital bicuspid aortic valve, rheumatic heart disease, and prior endocarditis may result in functional regurgitation [27]. In pregnancy with AR, diuresis is the choice of medicine with nitrates and hydralazine for reduction of afterload; besides, close monitoring after delivery is needed due to dramatic changes of hemodynamics that subsequently develop pulmonary edema and respiratory distress [8]. Mitral valve prolapses and rheumatic heart disease are responsible for the development of mitral regurgitation (MR) in pregnancy, and MR is tolerated in pregnancy when left ventricular function is normal [8]. Medicine therapy like diuresis and afterload reduction and close monitoring are needed to follow delivery to avoid developing pulmonary edema.

4.4. Stroke in Pregnancy. Stroke is a distinct unaware impairment of neurological function through the neuronal injury from a vascular incident that is one of the major leading causes of disability and death. In developed countries, stroke (ischemic stroke (IS) and hemorrhagic stroke (HS)) may be overwhelmingly complicated during pregnancy and increases maternal mortality and morbidity [28]. According to the survey data in the United States, approximately 7.4% of maternal death by a pregnancy-related stroke were subsequently found to increase in Canada by nearly 60%. It has been evidenced that stroke-related pregnancy is the major cause of hypertensive disorder in pregnancy which represent

![Figure 3: Flowchart of cardiac events during pregnancy.](image-url)
**Table 1: Management strategies of cardiac disease and stroke in pregnancy.**

| Hypertensive disorder of pregnancy (HDP) | Ischemic heart disease in pregnancy (IHD) | Vulvar heart disease in pregnancy | Stroke in pregnancy |
|-----------------------------------------|------------------------------------------|----------------------------------|---------------------|
| Prediagnosis to avoid pregnancy until control of hypertension or during pregnancy advise following below | Prediagnosis to delay pregnancy after treatment of IHD. If unexpected pregnant, then the following management | Pregnancy should be avoided in severe mitral and aortic valve disease. If unexpected pregnant, then the following management | Prediagnosis to control hypertension who has a previous history of preeclampsia |
| Investigation | Urine test for proteinuria. | | MRI images are considered an optimal modality during pregnancy, in case of missing timely taken MRI, then angiography CT and also perfusion CT can be chosen as a guide for proper interventional therapies. |
| | Ophthalmoscopic examination. | | MRI images are considered an optimal modality during pregnancy, in case of missing timely taken MRI, then angiography CT and also perfusion CT can be chosen as a guide for proper interventional therapies. |
| | Blood values | | MRI images are considered an optimal modality during pregnancy, in case of missing timely taken MRI, then angiography CT and also perfusion CT can be chosen as a guide for proper interventional therapies. |
| | USG | | MRI images are considered an optimal modality during pregnancy, in case of missing timely taken MRI, then angiography CT and also perfusion CT can be chosen as a guide for proper interventional therapies. |
| Risk factors | Hypertension, obesity, and family history of diabetes | Hypertension and preeclampsia are strongly associated with AMI. | Rheumatic fever is a most common | Preeclampsia, eclampsia |
| Pregnancy management | Close follow-up | Close follow-up | Close follow-up | Closely monitoring. Common drugs used: labetalol, atenolol, methyldopa, nifedipine, warfarin, and heparin (low molecular weight), and direct oral anticoagulants. |
| | Medical therapy: Nifedipine, methyldopa, labelotol, and hydralazine | Medical therapy: antiplatelet therapy, nitrates, beta-blockers, inotropes, and oxygen | Medical therapy for heart failure or arrhythmias | Medical therapy for heart failure or arrhythmias |
| | | Intervention: PCI and cardiac surgery | Balloon valvuloplasty or surgical valve replacement | Balloon valvuloplasty or surgical valve replacement |
| Delivery | Normal vaginal delivery unless cardiac and obstetrician indication. Continuous maternal cardiac monitoring. Continuous | If possible, vaginal delivery is preferred. Cesarean section is | | Vaginal delivery is the best approach if there is no obstetric contraindication. |
| | Emergency cesarean section if required | chosen when there is risk to the mother or fetus. Early delivery for clinical and hemodynamic worsening. | | | |
| Complication | Stroke, hypertension, and cardiac disease are responsible for the development of preeclampsia or eclampsia during pregnancy and also in postpartum | Cardiac arrest, heart failure, and ventricular tachycardia | Pulmonary edema, atrial arrhythmias, stroke, and heart failure | Reversible cerebral vasoconstriction syndrome can cause both ischemic and hemorrhagic stroke and the risk of cerebral venous sinus thrombosis (CVST). Long-term disability |
| Follow-up | The utility of subclinical vascular measurements, such as cerebral or peripheral vasomotor reactivity, carotid intimal medial thickness, coronary calcification, or clinical and biochemical biomarkers, is needed to identify women with a history of preeclampsia at increased risk of future stroke. | Maternal cardiac monitoring for at least 48 hours after delivery | | Counseling and cardiovascular screening of women who have a past history of preeclampsia. As well as correction of the other vascular risk factors. |
6.8% of maternal death in the US [29]; meanwhile, 40% to 70% of maternal death are due to preeclampsia which subsequently develop stroke as shown in Figure 4. Another study describes that 36% of pregnancy-associated strokes (PASs) occur as major causes of preeclampsia, and this preeclampsia later has 6-fold higher risk of stroke during puerperium [30]. Therefore, pregnancy-related stroke with preeclampsia may increase maternal mortality. Several studies reviewed and suggested that stroke is one of the risk factors during postpartum who has a history of either preeclampsia or eclampsia [31]. The pathophysiology and risk factors of preeclampsia and stroke are similar to hypertension, hypercoagulability, endothelial dysfunction, and dyslipidemia in addition cerebral vasomotor reactivity. The review of 31 pregnant women with stroke examined shows that 47% are ischemic strokes with preeclampsia and 43% are hemorrhagic strokes with preeclampsia. According to data from the United States, ischemic stroke and hemorrhagic stroke combined are detected as a risk in 30 per 100000 pregnancies [20]. However, it is established that hemorrhagic stroke is considered a common stroke found during pregnancy and postpartum associated with preeclampsia/eclampsia.

Arterial ischemic stroke is an emergency condition and should be started with initial management several studies’ recommendation; the management of stroke in pregnancy has similar to nonpregnant women as represented in

---

**Table 2: The imaging modalities in pregnancy.**

| Imaging modality       | Imaging finding                                                                 | Indications                                      |
|------------------------|---------------------------------------------------------------------------------|-------------------------------------------------|
| Electrocardiography    | The interpretation of ECG the heart rotates to the left with a 15–20° leftward axis deviation in most women in pregnancy. | Finding structural heart diseases               |
| Echocardiography       | Usually, some changes occur in echo parameters during pregnancy such as an increase in valve gradient, changes in the thickness of the LV wall, and dilation of the chamber quite mild. | Delivery of the status for the structures and functions of the heart |
| Chest radiography      | Diagnostic cardiovascular radiographic examination                             | The condition of the heart, lungs, airways, blood vessels, and the bones of the spine and chest showing by images |
| Computed tomography    | The X-rays reveal the images of the part of the body obtained in the various orthogonal plane. | Anomalous coronary artery and aortic dissection |
| Magnetic resonance imaging | Any abnormality of fetus                                                        | Congenital heart disease, aortic disease, and stroke |
| Ultrasonography        | Fetal heart rate, fetal position, and fetal presentation                        | The initial procedure for monitoring fetal well-being in pregnancy |

---

**Figure 4: Long-term and short-term effects of a pregnant mother with cardiac disease and stroke.**

---

Oxidative Medicine and Cellular Longevity
The miRNAs are noncoding RNA molecules, single-stranded with the family of short (19–25 nucleotides long); it is elaborate regulation of posttranscriptional gene through degrading mRNA or blocking its translation [36]. The genome is approximately 75% and 2% transcribed into RNA and gene with protein code, respectively; therefore, they preserve the normal cell function including cellular differentiation, proliferation, and apoptosis (Figure 6); bedside deregulations of these miRNAs may develop many diseases including preeclampsia in pregnancy. It has been documented the variable expression of miRNA in preeclamptic women which is represented in Table 3. The placenta, circulation, and umbilical vein show a specific pattern of miRNA and highly express MiR-141, miR-23a, miR-136, and some novel miRNA in the placenta [37]. The deregulations of miRNA indicate of disease condition, the higher miR-499a-5p expression in cerebrovascular and cardiovascular disease which is detected in the placenta of pregnancy-induced hypertension such as gestational hypertension and preeclampsia, whereas lower 26a-5p, miR-103a-3p, and miR-145-5p expressions are detected in the initial stage of preeclampsia (PE). However, the downregulated of the miR-548c-5p was detected in serum placental mononuclear cells in preeclampsia patients [38]. Consequently, these miRNAs act as a risk to increasing enduring cardiac disease in patients with preeclampsia. Therefore, the circulating miRNA in preeclampsia in pregnant women may consider a biomarker for initial recognition of diagnosis, monitoring, and follow-up preeclampsia during pregnancy. A previous study reported the upregulation of miR-210-3p and miR-210-5p was not only detected in preeclampsia, but also, miR-210 is present in pregnant heart failure patients [39]. There was deficiency data available for miRNA with stroke in pregnancy, but several studies reported miRNA is relevant

Table 1 [29]. However, the common imaging finding is shown in Table 2 [32–35]. Several studies safely performed chest X-ray during pregnancy which is represented in Figure 5.

5. miRNAs and Pregnancy-Related Cardiac Disease with Stroke

The miRNAs are noncoding RNA molecules, single-stranded with the family of short (19–25 nucleotides long); it is elaborate regulation of posttranscriptional gene through degrading mRNA or blocking its translation [36]. The genome is approximately 75% and 2% transcribed into RNA and gene with protein code, respectively; therefore, they preserve the normal cell function including cellular differentiation, proliferation, and apoptosis (Figure 6); bedside deregulations of these miRNAs may develop many diseases including preeclampsia in pregnancy. It has been documented the variable expression of miRNA in preeclamptic women which is represented in Table 3. The placenta, circulation, and umbilical vein show a specific pattern of miRNA and highly express MiR-141, miR-23a, miR-136, and some novel miRNA in the placenta [37]. The deregulations of miRNA indicate of disease condition, the higher miR-499a-5p expression in cerebrovascular and cardiovascular disease which is detected in the placenta of pregnancy-induced hypertension such as gestational hypertension and preeclampsia, whereas lower 26a-5p, miR-103a-3p, and miR-145-5p expressions are detected in the initial stage of preeclampsia (PE). However, the downregulated of the miR-548c-5p was detected in serum placental mononuclear cells in preeclampsia patients [38]. Consequently, these miRNAs act as a risk to increasing enduring cardiac disease in patients with preeclampsia. Therefore, the circulating miRNA in preeclampsia in pregnant women may consider a biomarker for initial recognition of diagnosis, monitoring, and follow-up preeclampsia during pregnancy. A previous study reported the upregulation of miR-210-3p and miR-210-5p was not only detected in preeclampsia, but also, miR-210 is present in pregnant heart failure patients [39]. There was deficiency data available for miRNA with stroke in pregnancy, but several studies reported miRNA is relevant
for diagnosis, prognosis, and therapeutic role of stroke. In present study reviews, similar deregulations of miRNA in stroke and preeclampsia in pregnancy which are represented in Table 3 [37, 40].

### 6. Pregnancy Outcomes

The multidisciplinary team may improve the management of heart disease during pregnancy; they should be more concerned during physiological changes in pregnancy in a woman who has a history of heart disease to avoid both maternal and fetal mortality and morbidity. The management protocol should be done before the conception and must be conducted by a collaborative team including an obstetrician and a cardiologist. It has been accounted that maternal cardiac disease causes fetal uteroplacental insufficiently due to inadequate maternal cardiac output [41]. The study reviewed six hundred forty-six pregnant women with vulvar disease including mitral stenosis, aortic stenosis, mitral regurgitation, and aortic regurgitation with reported 6% and 5% stillbirth, 6%, 4%, 6%, and 1% death, and 2 miscarriages, respectively [15]. Conversely, the survey study on

---

**Table 3: The different expressions of the miRNA in preeclampsia and stroke.**

| MicroRNAs | Preeclampsia | Source | Stroke | Source |
|-----------|--------------|--------|--------|--------|
| miR-145   | ↑            | Human maternal plasma | ↑      | Tissue/rat |
| miR-21    | ↑            | Human maternal plasma | ↑      | Tissue/rat |
| miR-210   | ↑            | Human placenta        | ↓      | Human blood |
| miR-26a   | ↑            | Human maternal plasma | ↓      | Tissue, blood/rat |
| miR-26b   | ↑            | Human maternal plasma | ↓      | Tissue, blood/rat |
| miR-328   | ↓            | Human placenta        | ↓      | Tissue, blood/rat |
| miR-29b   | ↑            | Primary human umbilical vein endothelial cells | ↑      | Tissue, blood/rat |
| miR-204   | ↑            | Human placenta        | ↑      | Tissue/rat |
| miR-23a   | ↑            | Human maternal plasma | ↑      | Tissue, blood/rat |
| miR-335   | ↑            | Human placenta        | ↓      | Tissue/rat |
| miR-150   | ↓            | Human placenta        | ↑      | Tissue, blood/rat |
| miR-126   | ↓            | Human placenta        | ↓      | Human blood |
| miR-155   | ↑            | Human placenta        | ↓      | Tissue, blood/rat |
| miR-451   | ↓            | Human maternal plasma | ↑      | Tissue, blood/rat |
| miR-107   | ↓            | Human maternal plasma | ↑      | Tissue, blood/rat |
| miR-185   | ↓            | Human maternal plasma | ↑      | Tissue, blood/rat |
ischemic heart disease (IHD) reported fetal and neonatal complications including 32% premature, 4% abortion, 1% neonatal death, 10% intrauterine growth restriction (IUGR), 28% low birth weight baby (LBW), 1% fetal hemorrhage, and 5% acute respiratory distress syndrome (ARDS) [42]. Several studies observe the pregnancy outcome in a woman with heart disease and found 20% attack adverse effects of neonates on the survey in Canada, according to Cardiac Disease in Pregnancy (CARPREG) [38]; besides, the multinational Registry of Pregnancy and Cardiac Disease (ROPAC) presented increase fetal and neonatal mortality and morbidity. The study of hypertensive disease with stroke during pregnancy found roughly fetal and neonatal complications including intrauterine growth restriction (IUGR), preterm delivery, prediabetes, and prehypertension that may lead to causes of increased mortality and morbidity [43–45].

7. Conclusions

Pregnancy-associated cardiovascular disease is a potential long-term consequence risk for maternal and fetal health. The general hemodynamic, hormonal, and metabolic variations during pregnancy state a significant physiological burden on the cardiovascular system. The physiological changes during pregnancy and postpartum predominate the progress of cardiovascular events, and exacerbation of preexisting cardiac disease may contribute to a higher maternal mortality rate. During pregnancy, the diversity of hypertension disease is made parallel the risk for stroke and cardiac disease in future life. These days, the miRNA biomarker is used as a marker of noninvasive, diagnostic, and prognostic for early exposure to pregnancy-related cardiac disease with its complications. Preconception counseling and early participation of a multidisciplinary team are indispensable for the effective management of these complications.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This work was funded by the Deanship of Scientific Research at Jouf University under grant No. DSR-2021-01-03162.

References

[1] A. A. Creanga, C. Syverson, K. Seed, and W. M. Callaghan, “Pregnancy-related mortality in the United States, 2011–2013,” Obstetrics and Gynecology, vol. 130, no. 2, pp. 366–373, 2017.
[2] J. Zollner, R. Curry, and M. Johnson, “The contribution of heart disease to maternal mortality,” Current Opinion in Obstetrics & Gynecology, vol. 25, no. 2, pp. 91–97, 2013.
[3] K. Pushpalatha, “Cardiac diseases in pregnancy—a review,” JJMSA, vol. 23, pp. 269–274, 2010.
[4] V. Regit-Zagrosek and C. Blomstlund Lundqvist, “ESC guidelines on the management of cardiovascular diseases during pregnancy: the task force on the management of cardiovascul-
lar diseases during pregnancy of the European society of cardiology (ESC),” European Heart Journal, vol. 32, no. 24, pp. 3147–3197, 2011.
[5] U. Elkayam, S. Goland, G. Petronella, and C. K. Silversides, “High-Risk Cardiac Disease in Pregnancy: Part I,” Journal of the American College of Cardiology, vol. 68, no. 4, pp. 396–410, 2016.
[6] J. J. Stuart, L. J. Tanz, N. R. Cook et al., “Hypertensive disorders of pregnancy and 10-year cardiovascular risk prediction,” Journal of The American College of Cardiology, vol. 72, no. 11, pp. 1252–1263, 2018.
[7] H. Lameijer, M. A. Kampman, M. A. Oudijk, and P. G. Pieper, “Ischaemic heart disease during pregnancy or post-partum: systematic review and case series,” Netherland's Heart Journal, vol. 23, no. 5, pp. 249–257, 2015.
[8] A. Sarah and C. C. Ward, “Congenital and acquired valvular heart disease in pregnancy,” Current Cardiology Reports, vol. 19, no. 10, pp. 1–7, 2017.
[9] P. Wu and P. Kelvin, “Temporal trends in pregnancy-associated stroke and its outcomes among women with hypertensive disorders of pregnancy,” Journal of the American Heart Association, vol. 9, no. 15, article e016182, 2020.
[10] T. Harsher, C. Lamy, and J. L. Mas, “Incidence and causes of strokes associated with pregnancy and puerperium. A study in public hospitals of Ile de France,” Stroke in Pregnancy Study Group. Stroke, vol. 26, pp. 930–936, 1995.
[11] S. D. Treadwell, B. Thanvi, and T. G. Robinson, “Stroke in pregnancy and the puerperium,” Postgraduate Medical Journal, vol. 84, no. 991, pp. 238–245, 2008.
[12] A. Fraser, S. M. Nelson, C. Macdonald-Wallis et al., “Associations of pregnancy complications with calculated cardiovascular disease risk and cardiovascular risk factors in middle age: the Avon Longitudinal Study of Parents and Children,” Circulation, vol. 125, no. 11, pp. 1367–1380, 2012.
[13] H. Huang, W. W. Li, J. Wu, M. Han, and B. H. Li, “The diagnostic value of circulating microRNAs in heart failure,” Experimental and Therapeutic Medicine, vol. 17, no. 3, pp. 2015–2019, 2019.
[14] S. E. Bowater and S. A. Thorne, “Management of pregnancy in women with acquired and congenital heart disease,” Postgraduate Medical Journal, vol. 86, no. 1012, pp. 100–105, 2010.
[15] M. Cauldwell, L. Baris, J. W. Roos-Hesselink, and M. R. Johnson, “Ischaemic heart disease and pregnancy,” Heart, vol. 105, no. 3, pp. 189–195, 2019.
[16] M. El Assar, J. Angulo, S. Vallejo, C. Peiró, C. F. Sánchez-Ferrer, and L. Rodríguez-Mañas, “Mechanisms involved in the aging-induced vascular dysfunction,” Frontiers in Physiology, vol. 3, p. 132, 2012.
[17] C. J. Nicholson, M. Sweeney, S. C. Robson, and M. J. Taggart, “Estrogenic vascular effects are diminished by chronological aging,” Scientific Reports, vol. 7, no. 1, p. 12153, 2017.
[18] Y. Okada, M. M. Galbreath, S. Shibata et al., “Relationship between sympathetic baroreflex sensitivity and arterial stiffness in elderly men and women,” Hypertension, vol. 59, no. 1, pp. 98–104, 2012.
[19] M. B. Pastore, S. O. Jobe, J. Ramadoss, and R. R. Magnness, “Estrogen receptor-and estrogen receptor- in the uterine vascular endothelium during pregnancy: functional implications for regulating uterine blood flow,” Seminars in Reproductive Medicine, vol. 30, no. 1, pp. 46–61, 2012.
[20] R. A. Ducas, D. A. Javier, R. D’souza, C. K. Silversides, and W. Tsang, “Pregnancy outcomes in women with significant valvular disease: a systematic review and meta-analysis,” *Heart*, vol. 106, no. 7, pp. 512–519, 2020.

[21] S. Laxmi, “Cardiovascular considerations in caring for pregnant patients: a scientific statement from the American Heart Association,” *Circulation*, vol. 141, no. 23, pp. e884–e903, 2020.

[22] M. C. Gongora and N. K. Wenger, “Cardiovascular complications of pregnancy,” *International Journal of Molecular Sciences*, vol. 16, no. 10, pp. 23905–23928, 2015.

[23] N. R. Smilowitz, N. Gupta, Y. Guo et al., “Acute myocardial infarction during pregnancy and the puerperium in the United States,” *Mayo Clinic Proceedings*, vol. 93, no. 10, pp. 1404–1414, 2018.

[24] J. Anthony, A. Osman, and M. U. Sani, “Valvular heart disease and pregnancy,” *Cardiovascular Journal of Africa*, vol. 27, no. 2, pp. 111–118, 2016.

[25] T. Guimarães, A. Magalhães, A. Veigaa, M. Fiuza, W. Ávila, and F. J. Pinto, “Heart disease and pregnancy: state of the art,” *Revista Portuguesa de Cardiologia*, vol. 38, no. 5, pp. 373–383, 2019.

[26] S. Routray, T. Mishra, S. Swain, U. Patnaik, and M. Behera, “Balloon mitral valvuloplasty during pregnancy,” *International Journal of Gynecology & Obstetrics*, vol. 85, no. 1, pp. 18–23, 2004.

[27] L. Baris, A. Hakeem, T. Moe et al., “Acute coronary syndrome and ischemic heart disease in pregnancy: data from the EURObservational Research Programme-European Society of Cardiology Registry of Pregnancy and Cardiac Disease,” *Journal of the American Heart Association*, vol. 9, no. 15, article e015490, 2020.

[28] R. H. Swartz, M. L. Cayley, N. Foley et al., “The incidence of pregnancy-related stroke: a systematic review and meta-analysis,” *International Journal of Stroke*, vol. 12, no. 7, pp. 687–697, 2017.

[29] E. C. Miller and L. Leffert, “Stroke in Pregnancy: a focused update,” *Anesthesia and Analgesia*, vol. 130, no. 4, pp. 1085–1096, 2020.

[30] E. C. Miller, H. J. Gatollari, G. Too et al., “Risk factors for pregnancy-associated stroke in women with preeclampsia,” *Stroke*, vol. 48, no. 7, pp. 1752–1759, 2017.

[31] C. Bushnell and M. Chireau, “Preeclampsia and stroke: risks during and after pregnancy,” *Stroke research and Treatment*, vol. 2011, Article ID 858134, 9 pages, 2011.

[32] K. Prokselj and M. Brida, “Cardiovascular imaging in pregnancy,” *International Journal of Cardiology Congenital Heart Disease*, vol. 5, article 100235, 2021.

[33] R. S. Plowman, C. Javidan-Nejad, C. A. Raptis et al., “Imaging of pregnancy-related vascular complications,” *Radiographics*, vol. 37, no. 4, pp. 1270–1289, 2017.

[34] L. Hacein-Bey, P. N. Varelas, J. L. Ulmer, L. P. Mark, K. Raghavan, and J. M. Provenzale, “Imaging of cerebrovascular disease in pregnancy and the puerperium,” *American Journal of Roentgenology*, vol. 206, no. 1, pp. 26–38, 2016.

[35] N. A. B. Ntusi, P. Samuels, S. Moosa, and A. O. Mocumbi, “Diagnosing cardiac disease during pregnancy: imaging modalities,” *Cardiovascular Journal Of Africa*, vol. 27, no. 2, pp. 95–103, 2016.

[36] A. Hornakova, Z. Kolkova, V. Holubekova et al., “Diagnostic potential of microRNAs as biomarkers in the detection of preeclampsia,” *Genetic Testing and Molecular Biomarkers*, vol. 24, no. 6, pp. 321–327, 2020.

[37] Z. Wang, P. Wang, Z. Wang et al., “miRNA-548c-5p downregulates inflammatory response in preeclampsia via targeting PTPRO,” *Journal of Cellular Physiology*, vol. 15, 2018.

[38] Y. Lv, C. Lu, X. Ji et al., “Roles of microRNAs in preeclampsia,” *Journal of Cellular Physiology*, vol. 234, no. 2, pp. 1052–1061, 2019.

[39] L. Aryan, L. Medzikovic, S. Umar, and M. Eghbali, “Pregnancy-associated cardiac dysfunction and the regulatory role of microRNA,” *Biology of Sex Differences*, vol. 11, 2020.

[40] H. Mirzaei, “Stroke in women: risk factors and clinical biomarkers,” *Journal of Cellular Biochemistry*, vol. 118, no. 12, pp. 4191–4202, 2017.

[41] M. Rachel, “Maternal cardiac output and fetal Doppler predict adverse neonatal outcomes in pregnant women with heart disease,” *Journal of the American Heart Association*, vol. 4, no. 11, article e002414, 2015.

[42] H. Lameijer, L. J. Burchill, L. Baris et al., “Pregnancy in women with pre-existent ischaemic heart disease: a systematic review with individualised patient data,” *Heart*, vol. 105, no. 11, pp. 873–880, 2019.

[43] K. Ramage, K. Grabowska, C. Silversides, H. Quan, and A. Metcalfe, “Association of adult congenital heart disease with pregnancy, maternal, and neonatal outcomes,” *JAMA Network Open*, vol. 2, no. 5, article e193667, 2019.

[44] W. Mark, “Risk of cardiovascular disease, end-stage renal disease, and stroke in postpartum women and their fetuses after a hypertensive pregnancy,” *American Journal of Physiology*, vol. 315, no. 3, pp. R521–R528, 2018.